ARVINAS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARVINAS, INC. stock issued during period, value, stock options exercised for the quarter ending 2023-03-31 was $1.50M, a 40.00% decline year-over-year.
- ARVINAS, INC. stock issued during period, value, stock options exercised for the quarter ending 2022-12-31 was $600.00K, a 84.62% decline year-over-year.
- ARVINAS, INC. stock issued during period, value, stock options exercised for the quarter ending 2022-09-30 was $1.10M, a 83.58% decline year-over-year.
- ARVINAS, INC. stock issued during period, value, stock options exercised for the quarter ending 2022-06-30 was $600.00K, a 83.33% decline year-over-year.
- ARVINAS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $4.80M, a 74.33% decline from fiscal 2021.
- ARVINAS, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $18.70M, a 128.05% increase from fiscal 2020.
- ARVINAS, INC. stock issued during period, value, stock options exercised for fiscal 2020 was $8.20M, a 192.86% increase from fiscal 2019.
- ARVINAS, INC. stock issued during period, value, stock options exercised for fiscal 2019 was $2.80M.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2023-03-31 | $1.50M 10-Q · filed 2023-05-05 | $3.80M derived: sum of 4 quarters · filed 2023-05-05 |
| 2022-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $4.80M 10-K · filed 2023-02-23 |
| 2022-09-30 | $1.10M 10-Q · filed 2022-11-09 | $8.10M derived: sum of 4 quarters · filed 2023-05-05 |
| 2022-06-30 | $600.00K 10-Q · filed 2022-08-04 | $13.70M derived: sum of 4 quarters · filed 2023-05-05 |
| 2022-03-31 | $2.50M 10-Q · filed 2023-05-05 | $16.70M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $18.70M 10-K · filed 2023-02-23 |
| 2021-09-30 | $6.70M 10-Q · filed 2022-11-09 | $19.79M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $3.60M 10-Q · filed 2022-08-04 | $13.67M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $4.50M 10-Q · filed 2022-05-05 | $11.35M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $4.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $8.20M 10-K · filed 2023-02-23 |
| 2020-09-30 | $577.30K 10-Q · filed 2021-11-03 | $4.23M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $1.28M 10-Q · filed 2021-08-05 | $5.03M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $1.35M 10-Q · filed 2021-05-04 | $4.15M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.80M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.38M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $399.49K 10-Q · filed 2020-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |